Research Analysts’ Recent Ratings Changes for Protagonist Therapeutics (PTGX)

A number of research firms have changed their ratings and price targets for Protagonist Therapeutics (NASDAQ: PTGX):

• 9/17/2025 – Protagonist Therapeutics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $72.00 price target on the stock.
• 9/17/2025 – Protagonist Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
• 9/16/2025 – Protagonist Therapeutics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $72.00 price target on the stock.
• 9/12/2025 – Protagonist Therapeutics was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 9/12/2025 – Protagonist Therapeutics is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $73.00 price target on the stock.
• 8/7/2025 – Protagonist Therapeutics had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 8/7/2025 – Protagonist Therapeutics had its price target raised by analysts at JMP Securities from $67.00 to $69.00. They now have a “market outperform” rating on the stock.

Insider Activity at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 10,415 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $54.78, for a total transaction of $570,533.70. Following the completion of the sale, the chief executive officer owned 520,603 shares in the company, valued at $28,518,632.34. The trade was a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $64.25, for a total value of $257,000.00. Following the sale, the director owned 5,130 shares of the company’s stock, valued at approximately $329,602.50. This represents a 43.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 70,859 shares of company stock valued at $3,944,577 in the last ninety days. 4.90% of the stock is currently owned by insiders.

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.